


PHARMACEUTICAL 2020

## Syndax Pharmaceuticals Inc Rank 270 of 362

Syndax 🌮







PHARMACEUTICAL 2020



## Syndax Pharmaceuticals Inc Rank 270 of 362

The relative strengths and weaknesses of Syndax Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syndax Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 71% points. The greatest weakness of Syndax Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 186% points.

The company's Economic Capital Ratio, given in the ranking table, is -404%, being 101% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	62,331
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,368
Liabilities, Non-Current	13,557
Other Assets	913
Other Compr. Net Income	25
Other Expenses	0
Other Liabilities	0
Other Net Income	1,492
Property and Equipment	281
Research and Development	42,994
Revenues	1,517
Selling, General and Administrative Expense	16,062

Output Variable	Value in 1000 USD
Assets	63,525
Liabilities	31,925
Expenses	59,056
Stockholders Equity	31,600
Net Income	-56,047
Comprehensive Net Income	-56,034
Economic Capital Ratio	-404%

